-+ 0.00%
-+ 0.00%
-+ 0.00%

According to the announcement of Tianjin Pharmaceutical Pharmaceutical, the company has received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for diphenhydramine hydrochloride approved by the State Drug Administration. The API meets the drug registration requirements, is approved for registration, and can be sold in the domestic market. Currently, the status is “A” on the CDE original auxiliary package registration information platform. Diphenhydramine hydrochloride is a first-generation antihistamine, mainly used to treat allergic dermatitis, urticaria, allergic rhinitis, etc. Up to now, the company has invested about 2.11 million yuan in R&D on this project. There is uncertainty about the drug's commissioning and subsequent market sales. Investors are kindly requested to pay attention to investment risks.

Zhitongcaijing·11/16/2026 07:49:09
Listen to the news
According to the announcement of Tianjin Pharmaceutical Pharmaceutical, the company has received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for diphenhydramine hydrochloride approved by the State Drug Administration. The API meets the drug registration requirements, is approved for registration, and can be sold in the domestic market. Currently, the status is “A” on the CDE original auxiliary package registration information platform. Diphenhydramine hydrochloride is a first-generation antihistamine, mainly used to treat allergic dermatitis, urticaria, allergic rhinitis, etc. Up to now, the company has invested about 2.11 million yuan in R&D on this project. There is uncertainty about the drug's commissioning and subsequent market sales. Investors are kindly requested to pay attention to investment risks.